Reclassifying severity after 48 hours could better predict mortality in acute respiratory distress syndrome.

Abstract:

BACKGROUND:Disease severity may change in the first week after acute respiratory distress syndrome (ARDS) onset. The aim of this study was to evaluate whether the reclassification of disease severity after 48 h (i.e. day 3) of ARDS onset could help in predicting mortality and determine factors associated with ARDS persistence and mortality. METHODS:We performed a secondary analysis of a 3-year prospective, observational cohort study of ARDS in a tertiary care referral center. Disease severity was reclassified after 48 h of enrollment, and cases that still fulfilled the Berlin criteria were regarded as nonresolving ARDS. RESULTS:A total of 1034 ARDS patients were analyzed. Overall hospital mortality was 57.7% (56.7%, 57.5%, and 58.6% for patients with initial mild, moderate, and severe ARDS, respectively, p = 0.189). On day 3 reclassification, the hospital mortality rates were as follows: resolved (42.1%), mild (47.9%), moderate (62.4%), and severe ARDS (76.1%) (p < 0.001). Patients with improving severity on day 3 had lower mortality (48.8%), whereas patients with the same or worsening severity on day 3 had higher mortality (62.7% and 76.3%, respectively). Patients who were older, had lower PaO2/FiO2, or higher positive end-expiratory pressure on day 1 were significantly associated with nonresolving ARDS on day 3. A Cox regression model with ARDS severity as a time-dependent covariate and competing risk analysis demonstrated that ARDS severity was independently associated with hospital mortality, and nonresolving ARDS had significantly increased hazard of death than resolved ARDS (p < 0.0001). Cumulative mortality curve for ARDS severity comparisons demonstrated significantly different (overall comparison, p < 0.001). CONCLUSIONS:Reclassification of disease severity after 48 h of ARDS onset could help to divide patients into subgroups with greater separation in terms of mortality. The reviews of this paper are available via the supplemental material section.

journal_name

Ther Adv Respir Dis

authors

Chiu LC,Lin SW,Liu PH,Chuang LP,Chang CH,Hung CY,Li SH,Lee CS,Wu HP,Huang CC,Li HH,Kao KC,Hu HC

doi

10.1177/1753466620936877

subject

Has Abstract

pub_date

2020-01-01 00:00:00

pages

1753466620936877

eissn

1753-4658

issn

1753-4666

journal_volume

14

pub_type

杂志文章
  • Use of temperature-controlled laminar airflow in the management of atopic asthma: clinical evidence and experience.

    abstract::Avoidance of allergens in the treatment of asthma has hitherto not achieved significant benefit despite the strong evidence that allergy both increases severity and contributes to exacerbations of asthma. House dust mite, cat and dog allergens are the most common perennial allergic triggers and most avoidance strategi...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章,评审

    doi:10.1177/1753465817690505

    authors: Warner JO

    更新日期:2017-04-01 00:00:00

  • Lung transplantation: a review of the optimal strategies for referral and patient selection.

    abstract::One of the great challenges of lung transplantation is to bridge the dichotomy between supply and demand of donor organs so that the maximum number of potential recipients achieve a meaningful benefit in improvements in survival and quality of life. To achieve this laudable goal is predicated on choosing candidates wh...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章,评审

    doi:10.1177/1753466619880078

    authors: Mitchell AB,Glanville AR

    更新日期:2019-01-01 00:00:00

  • Prognostic significance of forced vital capacity decline prior to and following antifibrotic therapy in idiopathic pulmonary fibrosis.

    abstract:BACKGROUND:Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal interstitial lung disease (ILD). Currently, two antifibrotic drugs are available for reducing forced vital capacity (FVC) decline in IPF. However, many pulmonologists wait before initiating treatment, especially when IPF patients have stable dise...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章

    doi:10.1177/1753466620953783

    authors: Aono Y,Nakamura Y,Kono M,Nakamura H,Yokomura K,Imokawa S,Toyoshima M,Yasui H,Hozumi H,Karayama M,Suzuki Y,Furuhashi K,Enomoto N,Fujisawa T,Inui N,Suda T

    更新日期:2020-01-01 00:00:00

  • Efficacy of direct hemoperfusion using polymyxin B-immobilized fiber column (PMX-DHP) in rapidly progressive interstitial pneumonias: results of a historical control study and a review of previous studies.

    abstract:BACKGROUND:Direct hemoperfusion using polymyxin B-immobilized fiber column (PMX-DHP) therapy has been approved for sepsis-associated acute respiratory distress syndrome, but its efficacy for other rapidly progressive interstitial pneumonias (RPIPs) is unclear. The purpose of this study was to examine the efficacy of PM...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章,评审

    doi:10.1177/1753465817708950

    authors: Ichiyasu H,Horio Y,Masunaga A,Migiyama Y,Sakamoto Y,Jodai T,Ideguchi H,Okabayashi H,Hamada S,Yoshida C,Hirosako S,Okamoto S,Kohrogi H

    更新日期:2017-07-01 00:00:00

  • Biomarkers in the diagnosis of pleural diseases: a 2018 update.

    abstract::The use of biomarkers on pleural fluid (PF) specimens may assist the decision-making process and enhance clinical diagnostic pathways. Three paradigmatic examples are heart failure, tuberculosis and, particularly, malignancy. An elevated PF concentration of the amino-terminal fragment of probrain natriuretic peptide (...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章,评审

    doi:10.1177/1753466618808660

    authors: Porcel JM

    更新日期:2018-01-01 00:00:00

  • Reduction of severe exacerbations and hospitalization-derived costs in alpha-1-antitrypsin-deficient patients treated with alpha-1-antitrypsin augmentation therapy.

    abstract:OBJECTIVE:Severe exacerbations in alpha-1-antitrypsin (AAT)-deficient patients with chronic obstructive pulmonary disease (COPD) and/or emphysema are a major cause of hospitalization. A multicentre, observational, retrospective study was undertaken to evaluate the effect of continuous AAT augmentation therapy in reduci...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章,多中心研究

    doi:10.1177/1753465812438387

    authors: Barros-Tizón JC,Torres ML,Blanco I,Martínez MT,Investigators of the rEXA study group.

    更新日期:2012-04-01 00:00:00

  • Electronic cigarettes: an aid in smoking cessation, or a new health hazard?

    abstract::The issue of electronic cigarettes is one of the most controversial topics in public health. There is intense debate and dividing opinions about their use patterns, health effects and association with smoking. This is expected since they were only recently introduced to the market and they refer to a harm-reduction ap...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章,评审

    doi:10.1177/1753465817744960

    authors: Farsalinos K

    更新日期:2018-01-01 00:00:00

  • Eradication of Pseudomonas aeruginosa in cystic fibrosis patients with inhalation of dry powder tobramycin.

    abstract:BACKGROUND:Pseudomonas aeruginosa (Pa) is the predominant pulmonary pathogen in patients with cystic fibrosis (CF). Tobramycin nebulization is used for the eradication of Pa infection. Nowadays, tobramycin dry powder inhalation (DPI) is available as well. This study reports the results of eradicating Pa with tobramycin...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章

    doi:10.1177/1753466620905279

    authors: Akkerman-Nijland AM,Yousofi M,Rottier BL,Van der Vaart H,Burgerhof JGM,Frijlink HW,Touw DJ,Koppelman GH,Akkerman OW

    更新日期:2020-01-01 00:00:00

  • Matrix metalloprotease polymorphisms are associated with gas transfer in alpha 1 antitrypsin deficiency.

    abstract:UNLABELLED:Alpha-1-antitrypsin deficiency [AATD] is associated with variable development of emphysema and other features of chronic obstructive pulmonary disease [COPD]. Matrix metalloproteinases [MMPs] are believed to be important in the pathophysiology of COPD, and may therefore confer susceptibility to this phenotyp...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章

    doi:10.1177/1753465809102263

    authors: McAloon CJ,Wood AM,Gough SC,Stockley RA

    更新日期:2009-02-01 00:00:00

  • Effectiveness of pharmacotherapy and behavioral interventions for smoking cessation in actual clinical practice.

    abstract:OBJECTIVES:This study evaluated the effectiveness of behavioral interventions (brief counseling, nonspecific psychological support in groups - NSGS and cognitive behavioral group therapy - CBGT) in combination with bupropion SR for smoking cessation in the field, through a smoking cessation clinic. METHODS:Two-hundred...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章,随机对照试验

    doi:10.1177/1753465809350653

    authors: Rovina N,Nikoloutsou I,Katsani G,Dima E,Fransis K,Roussos C,Gratziou C

    更新日期:2009-12-01 00:00:00

  • The once-daily fixed-dose combination of olodaterol and tiotropium in the management of COPD: current evidence and future prospects.

    abstract::Long-acting bronchodilators are the cornerstone of pharmacologic treatment of chronic obstructive pulmonary disease (COPD). Spiolto® or Stiolto® is a fixed-dose combination (FDC) containing two long-acting bronchodilators, the long-acting muscarinic receptor antagonist tiotropium (TIO) and the long-acting β2-adrenocep...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章,评审

    doi:10.1177/1753466619843426

    authors: Derom E,Brusselle GG,Joos GF

    更新日期:2019-01-01 00:00:00

  • Therapeutic perspectives in bronchial vascular remodeling in COPD.

    abstract::COPD may be characterized by significant changes in airway mucosal blood vessels, which may contribute to bronchial airway remodeling. The airway wall is more vascularized in COPD patients than in healthy subjects, though this phenomenon is less evident than in asthmatic patients. The vascular mucosal changes in the a...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章,评审

    doi:10.1177/1753465808092339

    authors: Zanini A,Chetta A,Olivieri D

    更新日期:2008-06-01 00:00:00

  • Current best practice in pulmonary rehabilitation for chronic obstructive pulmonary disease.

    abstract::Chronic obstructive pulmonary disease (COPD) is a chronic condition that negatively affects several patient-centered outcomes. Among these, exercise capacity, dyspnea, and quality of life are the most relevant. In this article, factors contributing to exercise limitation, increase in exercise-induced dyspnea, quality ...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章,评审

    doi:10.1177/1753465812444712

    authors: de Blasio F,Polverino M

    更新日期:2012-08-01 00:00:00

  • Leukotriene modifiers in the treatment of asthma in children.

    abstract::Asthma is one of the most common respiratory disorders in clinical practice, affecting up to 13% of people worldwide. Inflammation is the most important component of asthma and inhaled corticosteroids (ICS) are recommended as the first line controller treatment for patients of all ages. Treatment with corticosteroids ...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章,评审

    doi:10.1177/1753465809348014

    authors: del Giudice MM,Pezzulo A,Capristo C,Alterio E,Caggiano S,de Benedictis D,Capristo AF

    更新日期:2009-10-01 00:00:00

  • Beneficial role of vitamin D3 in the prevention of certain respiratory diseases.

    abstract::There is evidence of aberrations in the vitamin D-endocrine system in subjects with respiratory diseases. Vitamin D deficiency is highly prevalent in patients with respiratory diseases, and patients who receive vitamin D have significantly larger improvements in inspiratory muscle strength and maximal oxygen uptake. S...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章,评审

    doi:10.1177/1753465813503029

    authors: Luong KV,Nguyen LT

    更新日期:2013-12-01 00:00:00

  • Narrow-band imaging bronchoscopy in the detection of premalignant airway lesions: a meta-analysis of diagnostic test accuracy.

    abstract:OBJECTIVES:Both autofluorescence imaging bronchoscopy and narrow-band imaging have shown promise in the detection of premalignant airway lesions, each by utilizing different bandwidths of lights for better characterization of the mucosal and submucosal vascular grid. Since previously published meta-analyses have shown ...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章,meta分析

    doi:10.1177/1753465815589698

    authors: Iftikhar IH,Musani AI

    更新日期:2015-10-01 00:00:00

  • The safety of asthma medications during pregnancy: an update for clinicians.

    abstract::Pregnancy may be complicated by new onset or preexisting asthma. This article reviews the recognition and management of asthma during pregnancy, as well as general principles of asthma medication use during pregnancy. ...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章

    doi:10.1177/1753465814540029

    authors: Namazy JA,Schatz M

    更新日期:2014-08-01 00:00:00

  • Therapeutic management of patients with rheumatoid arthritis and associated interstitial lung disease: case report and literature review.

    abstract::Rheumatoid arthritis (RA) is an inflammatory autoimmune disease that can present different extrarticular manifestations involving heart, lungs and kidneys. In recent years there has been a growing awareness of the central role played by the lungs in the onset and progression of RA. In particular interstitial lung dise...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章,评审

    doi:10.1177/1753465816668780

    authors: Picchianti Diamanti A,Markovic M,Argento G,Giovagnoli S,Ricci A,Laganà B,D'Amelio R

    更新日期:2017-01-01 00:00:00

  • Surfactant protein D: a lung specific biomarker in COPD?

    abstract::A major impediment in the development of novel drugs for chronic obstructive pulmonary disease (COPD) has been the scarcity of a well-validated, robust, and easily obtainable intermediate end point such as serum biomarkers. To date the best serum biomarkers in COPD have been non-speci"c pro-in"ammatory molecules synth...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章,评审

    doi:10.1177/1753465808088903

    authors: Sin DD,Pahlavan PS,Man SF

    更新日期:2008-04-01 00:00:00

  • Early predictors for mechanical ventilation in COVID-19 patients.

    abstract:OBJECTIVE:To identify potential predictors for invasive and non-invasive mechanical ventilation in coronavirus disease 2019 (COVID-19) patients. METHODS:This study retrospectively analyzes data of 516 patients with confirmed COVID-19, who were categorized into three groups based on which mechanical ventilation method ...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章

    doi:10.1177/1753466620963017

    authors: Li W,Lin F,Dai M,Chen L,Han D,Cui Y,Pan P

    更新日期:2020-01-01 00:00:00

  • An immunological overview of allergen specific immunotherapy -- subcutaneous and sublingual routes.

    abstract::Allergen-specific immunotherapy remains the most likely effective treatment modality for allergic disorders by targeting the underlying immune mechanisms and possibly causing modifications in the disease course, as well as treating the symptoms. Treatment and compliance experiences been gained over nearly a century in...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章,评审

    doi:10.1177/1753465809349522

    authors: Ozdemir C

    更新日期:2009-10-01 00:00:00

  • The impact of comorbidities on mortality among men and women with COPD: report from the OLIN COPD study.

    abstract:BACKGROUND:Comorbidities probably contribute to the increased mortality observed among subjects with chronic obstructive pulmonary disease (COPD), but sex differences in the prognostic impact of comorbidities have rarely been evaluated in population-based studies. The aim of this study was to evaluate the impact of com...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章

    doi:10.1177/1753466619860058

    authors: Sawalha S,Hedman L,Backman H,Stenfors N,Rönmark E,Lundbäck B,Lindberg A

    更新日期:2019-01-01 00:00:00

  • New strategies in immunotherapy for lung cancer: beyond PD-1/PD-L1.

    abstract::Immunotherapy has significantly altered the treatment landscape for many cancers, including non-small cell lung cancer (NSCLC). Currently approved immuno-oncology agents for lung cancer are aimed at the reversal of immune checkpoints, programmed death protein-1 (PD-1) and programmed death ligand-1 (PD-L1). Although re...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章,评审

    doi:10.1177/1753466618794133

    authors: Villanueva N,Bazhenova L

    更新日期:2018-01-01 00:00:00

  • Reporting of central airway obstruction on radiology reports and impact on bronchoscopic airway interventions and patient outcomes.

    abstract:BACKGROUND:Central airway obstruction (CAO) is a serious condition that affects patients with both benign and malignant diseases. Timely recognition of CAO is crucial for prompt intervention aimed at improving the symptoms and quality of life of these patients. The aim of this study is to evaluate the formal radiology ...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章

    doi:10.1177/1753465815620111

    authors: Harris K,Alraiyes AH,Attwood K,Modi K,Dhillon SS

    更新日期:2016-04-01 00:00:00

  • Nivolumab for the treatment of Japanese patients with advanced metastatic non-small cell lung cancer: a review of clinical trial evidence for efficacy and safety.

    abstract::Programmed cell death (PD)-1 immune checkpoint inhibitors have emerged as promising options for the treatment of multiple cancer types. Nivolumab is a fully human immunoglobulin G4 monoclonal antibody, which inhibits the PD-1 receptor and has been approved in the United States, Europe, and Asia for the treatment of ad...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章,评审

    doi:10.1177/1753466618801167

    authors: Hida T

    更新日期:2018-01-01 00:00:00

  • The influence of speleotherapy combined with pulmonary rehabilitation on functional fitness in older adults - preliminary report.

    abstract:OBJECTIVE:Our aim was to determine the influence of pulmonary rehabilitation conducted in therapeutic salt mine chambers on the functional fitness of older adults. METHODS:The study included 22 individuals of age >65 years with chronic respiratory conditions. The patients underwent the Fullerton test before and after ...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章

    doi:10.1177/1753466620926952

    authors: Mętel S,Kostrzon M,Adamiak J,Gattner H,Kościelecka D,Sosulska A,Szczygieł E,Golec J

    更新日期:2020-01-01 00:00:00

  • Fluoroquinolones in the treatment of bronchopulmonary disease in cystic fibrosis.

    abstract::Fluoroquinolones are commonly used to treat lung infections in patients with cystic fibrosis. These patients are susceptible to lung infection with common bacteria such as Staphylococcus aureus and Haemophilus influenzae, but are also prone to infection by opportunistic bacteria, including Pseudomonas aeruginosa. The ...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章,评审

    doi:10.1177/1753465812459899

    authors: Hurley M,Smyth A

    更新日期:2012-12-01 00:00:00

  • Applications and mechanisms of immunotherapy in allergic rhinitis and asthma.

    abstract::Clinical and immunologic tolerance are hallmarks of successful allergen immunotherapy (AIT). Clinical benefits such as reduced symptoms, pharmacotherapy intake and improvement of quality of life persist following cessation of treatment. Successful AIT is associated with suppression of allergic inflammatory cells such ...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章,评审

    doi:10.1177/1753465816669662

    authors: Kappen JH,Durham SR,Veen HI,Shamji MH

    更新日期:2017-01-01 00:00:00

  • Clinical pulmonary infection score and a spot serum procalcitonin level to guide discontinuation of antibiotics in ventilator-associated pneumonia: a study in a single institution with high prevalence of nonfermentative gram-negative bacilli infection.

    abstract::Background We wanted to determine the impact of combined Clinical Pulmonary Infection Score (CPIS) and a spot serum procalcitonin (PCT)-guided protocol to shorten the duration of antibiotic treatment in patients with ventilator-associated pneumonia (VAP), mainly caused by nonfermentative gram-negative bacilli (NF-GNB)...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章

    doi:10.1177/1753466618760134

    authors: Wongsurakiat P,Tulatamakit S

    更新日期:2018-01-01 00:00:00

  • Comparison of the bronchodilator and systemic effects of AZD3199, an inhaled ultra-long-acting β₂-adrenoceptor agonist, with formoterol in patients with asthma.

    abstract:OBJECTIVES:Pharmacologically mediated bronchodilation is important in the management of asthma, and is primarily achieved with β₂-agonists. Novel compounds should preferably have a longer duration of action and a better systemic side effect profile than established alternatives at comparable peak bronchodilation. This ...

    journal_title:Therapeutic advances in respiratory disease

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1177/1753465813497527

    authors: Bjermer L,Rosenborg J,Bengtsson T,Lötvall J

    更新日期:2013-10-01 00:00:00